Chronic obstructive pulmonary disease
Conditions
Interventions
Trial group:none
Sponsors
Clinical Trial Center of Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Chronic obstructive pulmonary disease (COPD) patients >=18 years of age who meet the GOLD 2024 diagnostic criteria [GOLD 2024 criteria: patients with chronic respiratory symptoms such as dyspnoea, chronic cough or sputum and/or a history of exposure to risk factors, and pulmonary function tests showing: exertional expiratory volume in the first second after bronchodilator (FEV1)/exertional lung capacity (FVC) <0.7]; (2) Patients with a physician's diagnosis confirming the need for fibreoptic bronchoscopy and bronchoalveolar lavage during treatment; (3) Patients who are able to understand the nature, purpose, requirements, possible risks and adverse effects of the trial, and who have signed a written informed consent prior to the study.
Exclusion criteria
Exclusion criteria: (1) Subjects were excluded from the study for the presence of any of the following conditions: alpha-1 antitrypsin deficiency, asthma, active tuberculosis, pulmonary oedema, cystic fibrosis, occlusive bronchiectasis, tuberculosis (sarcoidosis), bronchiectasis, and unstable sleep apnoea; (2) Patients with haemosiderosis, needle-sickness, and a history of psychiatric and/or psychological disorders; (3) A history of pre-existing or current serious cardiovascular disease, including but not limited to: a. Signatory informed cardiac function class III/IV (based on New York Heart Association (NYHA) cardiac function classification); b. Acute myocardial infarction, unstable angina/acute coronary artery syndrome, percutaneous coronary intervention, coronary artery bypass grafting, within 6 months prior to signatory informed; c. Structural heart disease, e.g., hypertrophic cardiomyopathy, severe valvular disease; d. Structural heart disease, e.g., hypertrophic cardiomyopathy, severe valvular disease. heart disease such as hypertrophic cardiomyopathy, moderate to severe valvular disease; (4) Patients who are allergic to anaesthetics and who are unable to cooperate with fibrinoscopy; (5) Patients with uncontrollable bleeding due to severe coagulation disorders; (6) Patients at risk of rupture of aortic aneurysm; (7) Patients who have undergone pneumonectomy or who have undergone lung reduction surgery within 1 year prior to signing the PIC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of budesonide in bronchoalveolar Lavage Fluid;Concentration of budesonide in plasma; | — |
Countries
China
Contacts
Public ContactGuoping Yang
the Third Xiangya Hospital, Central South University
Outcome results
None listed